Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00049166
Status:
COMPLETED
Last Update Posted:
2013-09-30
First Post:
2002-11-12
Brief Title:
Erlotinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Mouth or Throat Cancer
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Study Overview
Official Title:
A Phase I Study of OSI-774 in Combination With Standard Fractionation Radiation Therapy in Patients With Oral Cavity or Oropharyngeal Cancer Stage II or III and in Combination With Standard Fractionation Radiation Therapy and Low Dose Daily Cisplatin in Patients With Oral Cavity or Oropharyngeal Cancer Stage III and IV
Status:
COMPLETED
Status Verified Date:
2013-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Phase I trial to study the effectiveness of combining erlotinib with radiation therapy with or without cisplatin in treating patients who have advanced mouth or throat cancer Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth Radiation therapy uses high-energy x-rays to damage tumor cells Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die Combining erlotinib with radiation therapy with or without cisplatin may kill more tumor cells
Detailed Description:
PRIMARY OBJECTIVES
I Determination of the maximally tolerated dose MTD of the combination of daily oral OSI-774 and standard fractionation external beam radiation therapy in patients with oral cavity OC or oropharyngeal OP squamous cell carcinoma SCC stage II and III
II Determination of the MTD of daily oral OSI-774 low dose daily cisplatin at 6 mgm2day and standard fractionation external beam radiation therapy in patients with oral cavity or oropharyngeal SCC stage III and IV
III Determination of the safety of chronic oral dosing of OSI-774 after radiation therapy
SECONDARY OBJECTIVES
I Determination of biological markers of activity of OSI-774 in tumor biopsy specimens from patients with SCC of OC and OP pre and post therapy
II Determination of the ability of 18F-FDG-PET scan to demonstrate biological activity of OSI-774 in previously untreated patients with SCC of the OC and OP and to predict for clinical response
OUTLINE This is a multicenter dose-escalation study of erlotinib Patients are assigned to 1 of 2 regimens according to disease stage
Regimen A patients with stage II T2 N0 or III T1-2 N1 disease Patients receive oral erlotinib once daily Beginning on day 15 patients also undergo intensity-modulated radiotherapy IMRT once daily 5 days a week for 7 weeks
Regimen B patients with stage III T3 N0-1 or IV T1-4 N2-3 M0 or T4 N0-1 M0 disease Patients receive oral erlotinib and undergo IMRT as in regimen A Patients also receive cisplatin IV over 20 minutes on each day of radiotherapy
Patients in both regimens continue to receive erlotinib until the last day of IMRT patients already in the maintenance phase of this study as of 51104 continue to receive erlotinib once daily for up to 2 years in the absence of disease progression or unacceptable toxicity
In both regimens cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose MTD is determined The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity
Patients are followed at 30 days and then every 3 months for up to 2 years
PROJECTED ACCRUAL A total of 24-48 patients 12-24 per regimen will be accrued for this study within 6-24 months
I Determination of the maximally tolerated dose MTD of the combination of daily oral OSI-774 and standard fractionation external beam radiation therapy in patients with oral cavity OC or oropharyngeal OP squamous cell carcinoma SCC stage II and III
II Determination of the MTD of daily oral OSI-774 low dose daily cisplatin at 6 mgm2day and standard fractionation external beam radiation therapy in patients with oral cavity or oropharyngeal SCC stage III and IV
III Determination of the safety of chronic oral dosing of OSI-774 after radiation therapy
SECONDARY OBJECTIVES
I Determination of biological markers of activity of OSI-774 in tumor biopsy specimens from patients with SCC of OC and OP pre and post therapy
II Determination of the ability of 18F-FDG-PET scan to demonstrate biological activity of OSI-774 in previously untreated patients with SCC of the OC and OP and to predict for clinical response
OUTLINE This is a multicenter dose-escalation study of erlotinib Patients are assigned to 1 of 2 regimens according to disease stage
Regimen A patients with stage II T2 N0 or III T1-2 N1 disease Patients receive oral erlotinib once daily Beginning on day 15 patients also undergo intensity-modulated radiotherapy IMRT once daily 5 days a week for 7 weeks
Regimen B patients with stage III T3 N0-1 or IV T1-4 N2-3 M0 or T4 N0-1 M0 disease Patients receive oral erlotinib and undergo IMRT as in regimen A Patients also receive cisplatin IV over 20 minutes on each day of radiotherapy
Patients in both regimens continue to receive erlotinib until the last day of IMRT patients already in the maintenance phase of this study as of 51104 continue to receive erlotinib once daily for up to 2 years in the absence of disease progression or unacceptable toxicity
In both regimens cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose MTD is determined The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity
Patients are followed at 30 days and then every 3 months for up to 2 years
PROJECTED ACCRUAL A total of 24-48 patients 12-24 per regimen will be accrued for this study within 6-24 months
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| U01CA070095 | NIH | CTEP | httpsreporternihgovquickSearchU01CA070095 |
| NCI-2012-03155 | REGISTRY | None | None |
| NCI-5375 | None | None | None |
| JHOC-20020723 | None | None | None |
| JHOC-J0174 | None | None | None |
| 5375 | OTHER | None | None |
| 5375 | OTHER | None | None |